Page 4 - Ted Tenthoff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ted tenthoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ted Tenthoff Today - Breaking & Trending Today

ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript

ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

United States , Vifor Pharma , Thomas Schall , Raymond James , Ted Tenthoff Piper Sandler , Michelle Gilson , Hidradenitis Suppurativa , Steve Seedhouse , Dburns Mcclellan , Susan Kanaya , Yanan Zhu , Red White , Thomasj Schall , Michelle Gilson Canaccord Genuity , Susanm Kanaya , Ryan Deschner , Piper Sandler , Ryan Deschner Raymond James , Ted Tenthoff , Lee Roth , Joseph Schwartz , American Association Of Dermatology , Exchange Commission , American Association For Cancer Research , European Medicines Agency , Devices Agency ,

IMV Inc. (IMV) Q1 2021 Earnings Call Transcript

Operator
Good morning, and thank you for standing by. Welcome to the IMV Inc. first-quarter 2021 conference call. [Operator instructions] I would now like to hand the conference over to Pierre Labbé, chief financial officer.
Thank you. Please go ahead.
Pierre Labbe
Chief Financial Officer
Thank you, Takke. Good morning, everyone. My name is Pierre Labbé, CFO at IMV, and I m pleased to welcome you to our clinical and operational update and first-quarter financial results conference call. I m joined today by Fred Ors, our chief executive officer; and Andrew Hall, our chief business officer, who will be available for the question-and-answer period at the end of the call. ....

United States , Wayne Pisano , Kaveri Pohlman , Michael Kalos , Ted Tenthoff Piper Sandler , Eli Lilly , Pierre Labb , Merck Keytruda , Yves Fradet , Chelsea Stellick , Andrew Hall , Joanne Schindler , Piper Sandler , Tom Shrader , Kyle Kuvalanka , James Hall , Joe Pantginis , Pierre Labbe , Ted Tenthoff , Imv Inc , University Laval In Qu , Research Center , University Of Pennsylvania , Providence Cancer Institute In Portland , Health Canada , Fred Ors ,

Gamida Cell Ltd. (GMDA) Q1 2021 Earnings Call Transcript

GMDA earnings call for the period ending March 31, 2021. ....

United States , Kiryat Gat , Josh Hamermesh , Jonathan Miller Evercore , Jason Butler , Gregory Renza , Ted Tenthoff Piper Sandler , Jonathan Miller , Piper Sandler , Vernon Bernadino , Michele Korfin , Ted Tenthoff , Shai Lankry , Tracey Ludy , Julian Adams , Ronit Simantov , Israeli Innovation Authority , Motley Fool Gamida Cell Ltd , Hadassah University , Gamida Cell Ltd , Gamida Cell , Motley Fool Gamida Cell , Call Transcript , Motley Fool Logo , Cell Ltd , Risk Factors ,

Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript

Operator
Good day, ladies and gentlemen and welcome to the Fate Therapeutics First Quarter 2021 Financial Results Conference Call. This call is being webcast live on the Investors section of Fate Therapeutics website at fatetherapeutics.com. [Operator Instructions]
I will now turn the call over to Scott Wolchko, President and CEO of Fate Therapeutics. Scott, you may begin.
Scott Wolchko
President And Chief Executive Officer
Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics first quarter 2021 financial results call. Shortly after 4:00 p.m. Eastern Time today, we issued a press release with these results, which can be found on the Investors section of our website under Press Releases. In addition, our Form 10-Q for the quarter ended March 31, 2021 was filed shortly thereafter and can be found on the Investors section of our website under Financial Information. Before we begin, I would like to remind everyone that except for ....

United States , Robyn Karnauskas , Jeff Miller , Ted Tenthoff Piper Sandler , Alethia Young Cantor , Sarah Cooley , Alethia Young , Wayne Chu , Michael Yee , Peter Lawson , Edward Dulac , Yigal Nochomovitz , Scott Wolchko , Piper Sandler , Bob Valamehr , Sloan Kettering , Ed Dulac , Robyn Karnauskas Truist , Michael Yee Jefferies , Ted Tenthoff , Peter Lawson Barclays , Yigal Nochomovitz Citi , Development Officer , American Society Of Clinical Oncology Annual Meeting , Fate Therapeutics Inc , American Society Of Gene ,

Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call Transcript

Operator
Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I will now turn the call over to your host, Malin Deon with Jounce Therapeutics. Please go ahead.
Malin Deon
Manager, Investor Relations & Corporate Communications
Thank you, operator. Good morning, and welcome to the Jounce Therapeutics first quarter conference call. This morning we issued a press release which outlines the topics that we plan to discuss today. The release is available in the Investors and Media section of our website at www.jouncetx.com.
Speaking on today s call will be our CEO and President, Dr. Rich Murray, who will review our pipeline progress, and key milestones, followed by our CSO, Dr. Dmitri Wiederschain, who will discuss our discovery efforts. Our CMO, Dr. Beth Trehu will then provide an update on our clinical activities, and lastly, our CFO, Kim Drapkin will review our first quar ....

Erich Murray , Raymond James , Edward Tenthoff Piper Sandler , Steve Seedhouse , Dmitri Wiederschain , Dmitri Wiederschainside , Swayam Ramakanth , Richard Murray , Nick Abbott , Beth Trehu , Kim Drapkin , Piper Sandler , Ryan Deschner , Zegbeh Jallah , Elizabeth Trehu , Malin Deon , Ted Tenthoff , Colleen Casey , Ryan Deschner Raymond James Financial Inc Analyst , Boris Peaker Cowen Co , Zegbeh Jallah Roth Capital Partners , Ramakanth Swayampakula Hc Wainwright Co , Investor Relations Corporate Communications , Jounce Therapeutics Inc , Jounce Therapeutics , Jounce Therapeutics First Quarter ,